Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Encorafenib Oral Capsule, Encorafenib
Encorafenib+ Cetuximab · 1 trial · 2 indications
with centralised review after neoadjuvant treatment with encorafenib and cetuximab, in patients with RAS wild type localised colon or upper rectum cancer (CC) and carriers of the BRAF V600E mutation.
| Arm | Type | Description |
|---|---|---|
| Encorafenib + Cetuximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Encorafenib Oral Capsule + Cetuximab | DRUG | Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks. |
Inclusion Criteria: * Informed consent signed and dated by the patient and the investigator * Age ≥18 years at time of informed consent * Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined ...
Top 20 of 77 competitors
Encorafenib is an investigational small molecule being studied for the treatment of BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E colorectal cancer. It is being evaluated in combination with other agents such as cetuximab and binimetinib in clinical trials.
Encorafenib targets kinases, as it belongs to the -nib class of kinase inhibitors. It is specifically being studied in patients with BRAF V600E mutations, indicating its role in targeting the BRAF V600E-mutant pathway in colorectal cancer.
Encorafenib is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with BRAF V600E-mutant colorectal cancer.
Encorafenib is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Multiple Phase 2 trials are ongoing or completed to assess its effectiveness in treating BRAF V600E-mutant colorectal cancer.
Encorafenib is being studied in several Phase 2 trials, including NCT03693170, NCT05004350, and NCT05706779. These trials evaluate combinations with cetuximab and binimetinib in patients with BRAF V600E-mutant colorectal cancer, with some trials completed and one currently recruiting.
Yes, Encorafenib is also known as Encorafenib Oral Capsule, Encorafenib Oral Capsule + Cetuximab, and Encorafenib + Cetuximab. These names refer to the same drug, often described in the context of its combination therapy with cetuximab for treating colorectal cancer.